Troller Cat Surpasses $350,000 in Contributions as Stage 14 of Presale Launches with New Referral Rewards and Staking Benefits
Each presale phase incorporates a viral or satirical reference to internet history, and Stage 14 continues that trend while introducing additional community-driven incentives. The token is now priced at $0.00009667, reflecting a 1833.4% increase from its Stage 1 price. As the project approaches its final presale phases, Troller Cat's team has also announced updates to its staking program and referral system to further enhance user engagement and participation.
New Milestones and Tokenomics Update
Since launching the first presale stage earlier this year, Troller Cat has steadily built momentum through a structured token release model. Each of the 26 stages is uniquely themed and tied to a set price increase. The listing price at the end of the presale has been set at $0.0005309, implying a projected return for participants who join before final stages conclude.
With over 372 billion total tokens and a 2-year liquidity lock in place, the project aims to implement a long-term deflationary token model. The deflationary mechanics will be supported by ad revenue from Troller Cat's upcoming Game Center and a token-burning protocol that gradually reduces circulating supply.
'We're not just aiming for virality; we're building a community experience that mirrors how internet culture evolves—spontaneously, with humor, but also with structure,' said a spokesperson from the Troller Cat development team.
69% APY Staking Introduced During Presale
Alongside the progression to Stage 14, Troller Cat has introduced a staking program offering up to 69% APY for participants who lock their tokens during the presale period. This initiative is designed to reward early backers and encourage longer-term holding behavior ahead of the token's listing on decentralized exchanges.
Unlike traditional staking protocols that launch post-ICO, the presale staking mechanism allows users to begin earning yield prior to listing, with rewards distributed upon token launch. The mechanism is non-custodial, meaning users retain ownership of their tokens while they are locked.
Referral Program Gains Traction
Troller Cat's referral rewards program has also seen expanded adoption. Any participant who contributes $25 or morein the presale unlocks access to a personalized dashboard where they can generate a unique referral code. When shared, both the referring user and the invitee receive an additional 10% in TCAT tokens, aligning community growth with token distribution.
According to the team, this structure has encouraged organic sharing and rapid user onboarding without relying on external promotional campaigns or influencer marketing. Instead, growth is fueled directly by the community through transparent and trackable incentives.
Gamified Presale Format
The current phase, 'Balloon Boy Hoax,' is one of several themed stages inspired by notable online hoaxes, pranks, and viral moments. Each new stage introduces updated visuals and minor platform tweaks while maintaining the project's overarching format. This approach aims to enhance community engagement and provide contextually rich milestones throughout the presale.
'This isn't just about memes—it's about digital culture, history, and creating a storyline that the crypto community can rally around,' the team spokesperson added.
With 12 presale stages remaining, each with an incrementally higher token price and decreasing token availability, the project expects to complete the presale within the next several weeks, depending on market participation and referral traction.
Community-Driven Approach
Troller Cat's whitepaper outlines plans for a post-launch ecosystem that includes: A Game Center integrating ad revenue sharing with token burns
integrating ad revenue sharing with token burns A liquidity lock mechanism to protect against early-stage volatility
mechanism to protect against early-stage volatility Governance tools to allow the community to vote on future stage themes and post-launch developments
The project has emphasized transparency and participation as core pillars of its strategy, publishing real-time presale metrics and circulating educational content to ensure users understand staking, referrals, and presale mechanics.
Token Allocation and Roadmap
The full token allocation includes: 40% allocated to presale
presale 10% to staking rewards
15% to ecosystem growth and development
20% to marketing and partnerships
15% reserved for centralized exchange liquidity and listings
Following the completion of Stage 26, Troller Cat is expected to list on Uniswap, where it will launch at the fixed price of $0.0005309. No new tokens will be minted post-launch, aligning with the deflationary structure and capped supply approach.
Key Figures Current Presale Stage: 14 of 26 ('Balloon Boy Hoax')
14 of 26 ('Balloon Boy Hoax') Token Price (Stage 14): $0.00009667
$0.00009667 Total Raised (as of July 19, 2025): Over $350,000
Over $350,000 Projected Listing Price: $0.0005309
$0.0005309 Maximum Token Supply: 372,000,000,000 TCAT
372,000,000,000 TCAT Liquidity Lock Duration: 2 years
2 years Staking Yield: Up to 69% APY
An example calculation provided by the project team illustrates that an investment of $35,000 at the current price would yield approximately 361,997,617 TCAT. If the token lists at its projected launch price, the value of that holding would be over $192,000, not including staking rewards.
Next Steps
The team has outlined the next steps in the roadmap, which include: Launch of the Troller Cat Game Center beta (Q4 2025)
NFT-based stage collectibles for early adopters (Q4 2025)
Expanded referral leaderboard and community reward programs
Uniswap listing targeted for completion shortly after Stage 26 ends
As the project transitions through the remaining 12 stages, it aims to build on its current momentum while introducing new platform features in tandem with community feedback.
About Troller Cat
Troller Cat ($TCAT) is an Ethereum-based meme coin project combining narrative-driven tokenomics with staking, referral mechanics, and community-led growth. With a 26-stage presale format inspired by viral internet events, Troller Cat aims to deliver a uniquely structured and engaging experience for crypto users of all experience levels.
For More Information
Media Contact:Troller Cat Team
Email: [email protected]
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 minutes ago
- New York Post
Left-wing hedge fund D.E. Shaw fears ‘reprisals' over DEI from Trump administration: sources
Staffers at the notoriously secretive hedge fund D.E. Shaw fear the wildly lucrative left-wing firm could face 'reprisals' from the Trump administration over its woke DEI policies, The Post has learned. The New York-based powerhouse founded by billionaire David E. Shaw — whose algorithm-driven trades made it the most profitable hedge fund in 2024, raking in $11.1 billion for investors, according to Institutional Investor magazine — has grown remarkably quiet of late when it comes to diversity, equality, and inclusion, sources said. D.E. Shaw did not respond to The Post's emailed request for comment for this article. 8 Billionaire David E. Shaw, who has a long history of donating to Democrats, founded the money-spinning firm in 1988. YouTube/WebsEdge Science The company, which gave a young Jeff Bezos his big break in finance before he set up Amazon in 1994, has promoted DEI policies for years. A June 2019 memo obtained by The Post that was written by managing director Eddie Fishman encouraged staffers 'to display their pronouns' that 'align with their gender identity' in their emails so managers could 'foster an inclusive culture.' 8 The June 2019 memo. Obtained by the NY Post But a review by The Post of archived pages from D.E. Shaw's website shows that its DEI language has since been scrubbed, including references to how the firm 'actively promotes LGBTQ+ inclusion.' Now, its site merely says it's seeking 'talented people with diverse perspectives and backgrounds.' One insider said top brass at the Wall Street firm — whose 74-year-old namesake helped bankroll the presidential campaigns of Kamala Harris, Joe Biden, Barack Obama and Hillary Clinton — made 'a strategic move' to steer away from full-throated wokeness over fear of catching the attention of the White House. 'There was some concern that aggressive policies would make the firm a target for reprisals by the current administration,' the source said. 'And we were about as aggressive as you could get.' 'They were going 100 miles an hour on DEI in public, only then to drop to zero and fall off a cliff,' said another staffer. 'The communications have certainly been ratcheted back,' claimed a third employee. 'It's not as in-your-face as it once was.' 8 Amazon founder Jeff Bezos met his ex-wife Mackenzie Scott while working at D.E. Shaw. The then-couple quit in 1994 when Bezos set up the online retail giant. REUTERS 8 Top DOJ lawyer Harmeet K. Dhillon issued a stern warning to corporate America in a Senate hearing on July 23: 'The goal is clear: either DEI will end on its own, or we will kill it.' CQ-Roll Call, Inc via Getty Images D.E. Shaw's retreat follows a Supreme Court ruling last month and a White House-led crackdown on corporate DEI policies, which critics say lower performance standards and foster so-called reverse discrimination. Top Department of Justice lawyer Harmeet K. Dhillon, the assistant attorney general for civil rights, issued the starkest of warnings to corporate America during a testimony to the Senate Judiciary Committee on July 23. 'The goal is clear: either DEI will end on its own, or we will kill it,' the top Trump administration official said. Nevertheless, five sources with direct knowledge of the matter told The Post that executives at the company — founded by computer scientist Shaw in 1988 after he did stints at Stanford, Columbia and Morgan Stanley — are still paying lip service to wokeness to the rank and file. 'They have said internally that our commitment and programs regarding DEI are not changing,' said another senior D.E. Shaw source, who spoke on condition of anonymity. 'They have themselves in a bit of a bind. They went hardcore DEI to appear progressive and cater to liberal recruits,' a veteran of the firm added. 'Internally, they are putting a brave face on it. But they are now very worried that the administration will start looking into them.' 8 President Trump has ordered the DOJ to crack down on the DEI policies that flourished under the Biden-Harris administration. Bloomberg via Getty Images 8 The woke job placements mysteriously disappeared from the DE Shaw website after The Post approached the firm for comment about its DEI policies. Fearing Trump's ire, the hedge fund appears to have axed its 'inclusive' Bridge internship. The program was set up in 2016 for 'historically underrepresented' groups in finance. The 'woke' job placement schemes still featured prominently on D.E. Shaw's website last week. But they have now been deleted after The Post approached the firm for comment on their DEI policies on Friday. According to an archived version of D.E. Shaw's Campus website — an online recruitment portal — the firm created three programs aimed at diverse recruitment. Its 'Discovery' program was 'designed for students who self-identify as women', while 'Momentum' was aimed at those 'who self-identify as part of the LGBTQIA+ community D.E. Shaw also had a program called 'Latitude,' which was 'for students who self-identify as Native American or Alaska Native, Black or African American, Hispanic or Latino, or Native Hawaiian or Other Pacific Islander.' 8 One scheme called Momentum was open to students who self-identify as part of the 'LGBTQIA+ community.' Other Wall Street giants including Goldman Sachs, BlackRock, Bank of America and Jamie Dimon's JPMorgan Chase have scaled back their public commitments to DEI. The Post reported exclusively how Goldman decided to give woke the boot — on its website at least — when its partners met with CEO David Solomon in Miami in February. The Post attempted to speak to additional employees at D.E. Shaw, but they declined, citing fears of retribution from D.E. Shaw's management, which has even been known to weigh in on whether employees can attend social gatherings with people who have left the company. 'It is definitely something that people are talking about at the firm,' a separate person briefed on the matter told The Post. 'The irony is that the whole firm is still very white and very male,' said another source. 8 Former Treasury Secretary Larry Summers is one of the biggest names among the DE Shaw alumni. He served both the second Clinton and first Obama administrations. Getty Images The hedge fund's leadership team counts two females, Alexis Halaby and managing director Anne Dinning, amongst its ranks. The firm last made major headlines in 2022 when it was forced to pay a $52 million defamation settlement to one of its former rising stars, Dan Michalow, after an arbitration panel found that it had falsely accused him of sexual misconduct. Michalow, who always denied any wrongdoing, left the company not long after the start of the #MeToo movement, where hundreds of rich and powerful men were accused of sexual misdeeds. Aside from Amazon's Bezos and his ex-wife, Mackenzie Scott, D.E. Shaw's most famous alum is arguably Lawrence Summers. He served as treasury secretary under Bill Clinton and as director of Barack Obama's National Economic Council.
Hamilton Spectator
18 minutes ago
- Hamilton Spectator
Audiense Launches MCP Connectors: Bringing Audience Intelligence into your AI Workflow
Fort Worth, TX, July 28, 2025 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE Audiense launches MCP Connectors: Bringing Audience Intelligence into your AI Workflow Fort Worth, TX – July 28, 2025 — Audiense, the leading audience intelligence platform, today unveiled its MCP (Model Context Protocol) connectors – seamless integrations that bring audience insights directly into AI tools like Claude and ChatGPT. This marks a major leap forward in how marketing, research, and strategy teams work with audience insights – making them accessible, actionable, and customizable, without a single line of code. Bringing Audience Intelligence into the AI Ecosystem The new MCP connectors act as real-time bridges between all Audiense consumer intelligence products (including Insights, SOPRISM, Demand, and Tweet Binder) and today's leading generative AI platforms. Instead of pulling data manually or scanning through insights, users can interact with audience data directly within the AI tools they're already using and generate outputs like: All using simple prompts, bringing audience intelligence into their everyday workflows, instantly and intuitively. 'AI isn't just a productivity hack; it's becoming the new interface for how brands engage with their audiences. With MCP, we're embedding Audiense insights directly into that workflow, empowering users to interact with their audience segments in real-time, uncover deeper understanding, and shape strategy without friction. It's not just about working faster, it's about building smarter, more dynamic conversations with the people that matter most.' - Jim Swift, CEO of Audiense Built For How You Work Whether you're shaping strategy or executing creative, Audiense's MCP connectors are designed to support the way modern teams operate, helping them move faster, think deeper, and create better. For Marketers: Build campaign strategies, messaging frameworks, and creative briefs on the fly. For Analysts: Compare audience segments, spot trends, and test hypotheses without touching code. For Strategists: Uncover white space, surface opportunities, and turn audience insight into competitive advantage. For Content & Creative Teams: Generate content calendars, brainstorm ideas, and adapt tone of voice to each persona. 'This isn't just about saving time. It's about possibility. Whether you're writing a brief, testing a hypothesis, or developing an agent, MCP connectors give you a faster, more flexible way to turn insight into action.' - Javier Burón, Product Strategist at Audiense Rethinking How You Work with Insights MCP connectors are designed for speed, flexibility, and real-world applications – redefining how teams interact with insights and deliver outcomes. What sets MCP apart: This launch reaffirms Audiense's commitment to innovation and to building the future of audience intelligence alongside the evolution of AI. To learn more about the MCP connectors, read our latest blog or request a demo . About Audiense Audiense is an AI-powered suite of solutions that helps brands transform complex customer data into meaningful insights and measurable outcomes. Backed by PSG Equity, Audiense combines capabilities from location intelligence, ecommerce analytics, and real-time audience insights to deliver a holistic view of customer behavior, motivation, and intent. Built for strategy, marketing, and growth teams, Audiense empowers brands to engage the right people online and in person, and to personalize every interaction with clarity and precision. Media Contact: Saman Bhatti VP, Growth saman@
Hamilton Spectator
19 minutes ago
- Hamilton Spectator
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company's proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of HCC. HCC is the most common type of primary liver cancer, with GPC3 expressed in over 75% of cases1. ZW251 is a potential first-in-class ADC engineered to selectively target GPC3. It is composed of a humanized IgG1 antibody conjugated to a novel camptothecin-based TOPO1i using a validated peptide cleavable linker. A drug-antibody-ratio (DAR) of four was selected for ZW251 as a lower DAR potentially could unlock a broader range of dose levels, a potential benefit as HCC patients are commonly challenged by impairment of liver function as a result of chronic liver disease and cirrhosis. In preclinical studies, ZW251 demonstrated strong activity in a range of HCC models, including a range of patient derived xenografts exhibiting a breadth of GPC3 expression and noteworthy tolerability in non-human primate toxicology studies at doses up to 120 mg/kg. 'This advancement marks the second ADC from our wholly-owned pipeline, utilizing our proprietary TOPO1i payload, to progress into clinical development, reinforcing confidence in our approach,' said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. 'Like ZW191, which is currently in clinical trials, ZW251 utilizes the same payload paired with an optimized antibody. Our observations with ZW191 in the clinic to date provide a strong foundation as we initiate clinical development of this second ADC. With its novel design, unique mechanism of action, and promising preclinical activity, ZW251 offers the potential to meaningfully improve upon the current standard of care for HCC either as a monotherapy or in combination.' We plan to commence Phase 1 clinical studies for ZW251 in 2025. About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval and China' s NMPA granted conditional approval for zanidatamab to treat adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The European Commission (EC) has granted conditional marketing authorization for Ziihera® as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer previously treated with at least one prior line of systemic therapy. Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the U.S., Europe, and China. In addition, zanidatamab is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking Statements This press release includes 'forward-looking statements' or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the efficacy and safety of zanidatamab and Zymeworks' product candidates; ongoing clinical studies and regulatory reviews; the potential addressable market of zanidatamab and Zymeworks' product candidates; the timing of and results of interactions with regulators; Zymeworks' clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies, clinical trials and the related data; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' product candidates; and the commercial potential of technology platforms and product candidates. When used herein, words such as 'plan', 'believe', 'expect', 'may', 'anticipate', 'potential', 'will', 'intend', 'continues', 'progress', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials, including any required confirmatory trials, may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; conditional regulatory approval may be withdrawn or revoked if any of Zymeworks' or its partners' product candidates fail to satisfy the requirements of any such conditional regulatory approvals; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab and Zymeworks' product candidates may not be successfully commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under 'Risk Factors' in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at and ). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Contacts: Investor Inquiries: Shrinal Inamdar Senior Director, Investor Relations (604) 678-1388 ir@ Media Inquiries: Diana Papove Senior Director, Corporate Communications (604) 678-1388 media@ _______________________ 1 Wang HL et al., Arch Pathol Lab Med 2008.
